Drug Type Small molecule drug |
Synonyms Cefozopran, Cefozopran hydrochloride (JP17), SCE 2787 + [3] |
Target |
Mechanism PBPs inhibitors(Bacterial penicillin-binding protein inhibitors), Cell wall inhibitors |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date JP (01 Aug 1995), |
Regulation- |
Molecular FormulaC19H18ClN9O5S2 |
InChIKeyNTJHUKMPVIFDNY-XFDPNJHTSA-N |
CAS Registry113981-44-5 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D02233 | Cefozopran Hydrochloride |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Bacterial Infections | JP | 20 Oct 1995 | |
Adnexitis | JP | 01 Aug 1995 | |
Cholangitis | JP | 01 Aug 1995 | |
Cholecystitis | JP | 01 Aug 1995 | |
Cystitis | JP | 01 Aug 1995 | |
Empyema | JP | 01 Aug 1995 | |
Hemorrhagic Septicemia | JP | 01 Aug 1995 | |
Keratitis | JP | 01 Aug 1995 | |
Laryngitis | JP | 01 Aug 1995 | |
Liver Abscess | JP | 01 Aug 1995 | |
Lung Abscess | JP | 01 Aug 1995 | |
Meningitis | JP | 01 Aug 1995 | |
Peritonitis | JP | 01 Aug 1995 | |
Pneumonia | JP | 01 Aug 1995 | |
Pyelonephritis | JP | 01 Aug 1995 | |
Secondary infection | JP | 01 Aug 1995 | |
Tonsillitis | JP | 01 Aug 1995 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
(non-specific) purulent meningitis | Phase 1 | CN | 14 Sep 2009 | |
Burns | Phase 1 | CN | 14 Sep 2009 | |
Chronic disease of respiratory system | Phase 1 | CN | 14 Sep 2009 | |
Connective tissue inflammation | Phase 1 | CN | 14 Sep 2009 | |
Endophthalmitis | Phase 1 | CN | 14 Sep 2009 | |
Intrauterine infection | Phase 1 | CN | 14 Sep 2009 | |
Orbital infection | Phase 1 | CN | 14 Sep 2009 | |
Otitis Media | Phase 1 | CN | 14 Sep 2009 | |
Paranasal Sinus Diseases | Phase 1 | CN | 14 Sep 2009 | |
Pelvic Inflammatory Disease | Phase 1 | CN | 14 Sep 2009 |